La cadena de opciones muestra datos clave de las opciones de acciones de aTyr Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para aTyr Pharma..

aTyr Pharma (NASDAQ:ATYR) Bolsa, Cadena de Opciones

aTyr Pharma

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma Inc

Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) has outperformed the market over the past 10 years by 3.51% on an annualized basis producing an average annual return of 14.71%. Currently, Ameriprise Finl has a market capitalization of $51.67 billion. 
Buying $100 In AMP: If an investor had bought $100 of AMP stock 10 years ago, it would be worth $398.78 today based on a price of $537.12 for AMP at the time of writing.
<h3>Ameriprise Finl's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738622708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

"Over the last few years, we proactively moved our U.S.-bound camera production outside of China, which has significantly reduced the impact of tariffs," said Brian McGee, CFO and COO of GoPro. "We are continuously evaluating and optimizing our supply chain to improve delivery of our products at lower cost."

Guidance

GPRO

GoPro Says Its Diversified Supply Chain Mitigates Potential Impact Of US Tariffs; Does Not Expect US Consumer Pricing Or Gross Margin To Be Materially Affected By Recent Tariff Announcements

Nauticus completed assembly and the first phase of acceptance testing at its Houston facility in January. This second Aquanaut vehicle is now in Louisiana undergoing the next phase of acceptance testing.
The vehicle should complete the required pool testing this month. Once completed, the vehicle will move to the final phase of testing in open water off the southern coast of the United States. Nauticus is targeting completion of all acceptance testing for this vehicle within the first quarter of 2025.

KITT

Nauticus Robotics Reports Assembly Completion Of Its Second Flagship Underwater Vehicle, Aquanaut Mark 2; Targets Completion Of All Acceptance Testing For This Vehicle Within Q1 Of 2025

Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) has outperformed the market over the past 10 years by 43.64% on an annualized basis producing an average annual return of 54.84%. Currently, Celsius Holdings has a market capitalization of $5.62 billion. 
Buying $1000 In CELH: If an investor had bought $1000 of CELH stock 10 years ago, it would be worth $80,089.89 today based on a price of $23.92 for CELH at the time of writing.
<h3>Celsius Holdings's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738621815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CELH

$1000 Invested In Celsius Holdings 10 Years Ago Would Be Worth This Much Today

Contracts

SATS

Tucows Subsidiary Wavelo Renews Four-year Contract To Provide Its Solutions For Echostar's Boost Mobile

Coca-Cola Consolidated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) has outperformed the market over the past 10 years by 18.62% on an annualized basis producing an average annual return of 29.82%. Currently, Coca-Cola Consolidated has a market capitalization of $11.93 billion. 
Buying $100 In COKE: If an investor had bought $100 of COKE stock 10 years ago, it would be worth $1,365.83 today based on a price of $1361.46 for COKE at the time of writing.
<h3>Coca-Cola Consolidated's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738620909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COKE

Here's How Much $100 Invested In Coca-Cola Consolidated 10 Years Ago Would Be Worth Today

NewMarket Expects Continued Strength In Both Petroleum Additives And Specialty Materials Segments

BRBR

BellRing Brands Raises FY25 Net Sales Outlook From $2.24B - $2.32B To $2.26B - $2.34B (Est $2.295B)

Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) reported second-quarter financial results Monday after the bell. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/02/n43448785/clorox-reports-q2-fiscal-year-2025-results-updates-outlook">of the report</a>.
Q2 Earnings: Clorox reported fiscal second-quarter revenue of $1.69 billion, beating the consensus estimate of $1.63 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The household consumer products company reported adjusted earnings of $1.55 per share, beating analyst estimates of $1.41 per share.
Clorox said net sales decreased 15% on a year-over-year basis. Health and Wellness sales fell 13%, Household sales decreased 11%, Lifestyle sales were down 16% and International sales fell 12%. 
Gross margin increased 30 basis points to&nbsp;43.8%, up from&nbsp;43.5%&nbsp;in the prior year&#8217;s quarter. Net cash provided by operations year-to-date came in at $401 million, up from $173 million year-over-year. 
Clorox ended the period with $290 million of cash and cash equivalents. 
&#8220;We achieved better-than-expected results across sales, margin and EPS in the&nbsp;second quarter&nbsp;due to our strong demand creation plans, which also supported our share growth,&#8221; said&nbsp;Linda Rendle, chair and CEO of Clorox.
&#8220;We are further advancing our transformation as we embark upon a significant milestone with our Enterprise Resource Planning transition in the U.S., resulting in our updated outlook. I am confident that we are taking the right actions to deliver strong financial performance and long-term, profitable growth.&#8221;
Outlook: Clorox raised its full-year earnings forecast from a range of $6.65 to $6.90 per share to a new range of $6.95 to $7.35 per share versus estimates of $6.84 per share. The company also guided for 2025 net sales in a range of down 1% to up 2%. 
CLX Price Action: <a href="http://benzinga.com/quote/clx">Clorox shares</a> were down 2.28% after-hours, trading at $155.13 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43449997/nxp-semiconductors-reports-better-than-expected-q4-results-details">NXP Semiconductors Reports Better-Than-Expected Q4 Results: Details</a></li>
</ul>
Photo: Shutterstock.
&nbsp;

Earnings

After-Hours Center

Movers

Clorox Stock Slides On Q2 Earnings

United Rentals has elected to withdraw and refile its Premerger Notification and Report Form, which was initially filed on January 16, 2025, to provide the FTC with additional time for review, given the abbreviated 15-day review period associated with cash tender offers. Upon such refiling, the 15-day waiting period under the HSR Act restarted, with the new waiting period expiring at 11:59 P.M., Eastern Time, on February 18, 2025.
 &nbsp;

HEES

United Rentals Reveals Notice Of Withdrawal And Refiling Of Premerger Notification And Report Form Under HSR Act In Connection With Pending Acquisition Of H&E Equipment Services

Offerings

CTCX

Carmell Files For Mixed Shelf Of Up To $100M - Filing

AVAV

AeroVironment Secures Third Delivery Order Totaling $288M Of Switchblade Loitering Munition Systems As Part Of US Army's Directed Requirement For Lethal Unmanned Systems

NewMarket (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEU#NYSE">NEU</a>) reported quarterly earnings of $11.56 per share. This is a 37.95 percent increase over earnings of $8.38 per share from the same period last year. The company reported $654.65 million in sales this quarter. This is a 1.76 percent increase over sales of $643.35 million the same period last year.

NewMarket Q4 2024 GAAP EPS $11.56 Up From $8.38 YoY, Sales $654.65M Up From $643.35M YoY

BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.48 by 20.83 percent. This is a 34.88 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $532.90 million which beat the analyst consensus estimate of $525.17 million by 1.47 percent. This is a 23.82 percent increase over sales of $430.40 million the same period last year.

Earnings Beats

BellRing Brands Q1 2025 Adj EPS $0.58 Beats $0.48 Estimate, Sales $532.90M Beat $525.17M Estimate

A second major development in the tariff political drama came late Monday as the United States and Canada reached an agreement to pause Donald Trump&#8217;s proposed trade levies <a href="https://www.benzinga.com/topic/tariffs">&#8220;for at least 30 days.&#8221;</a>
Canadian Prime Minister Justin Trudeau announced the deal on social media platform X following a phone call with Trump. 
The tariff deal includes new border security commitments to combat fentanyl trafficking and organized crime, mirroring Trump's agreement with <a href="https://www.benzinga.com/government/regulations/25/02/43440692/us-mexico-agrees-on-one-month-tariffs-pause-stocks-rebound-peso-rallies">Mexican President Claudia Sheinbaum.</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I just had a good call with President Trump. Canada is implementing our $1.3 billion border plan — reinforcing the border with new choppers, technology and personnel, enhanced coordination with our American partners, and increased resources to stop the flow of fentanyl. Nearly…
&mdash; Justin Trudeau (@JustinTrudeau) <a href="https://twitter.com/JustinTrudeau/status/1886529228193022429?ref_src=twsrc%5Etfw">February 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Canada Rolls Out $1.3 Billion Border Plan</h3>
Trudeau outlined a $1.3 billion border reinforcement initiative featuring:
<ul>
<li>Deployment of nearly 10,000 frontline personnel equipped with new helicopters, surveillance technology and enhanced coordination with U.S. agencies.</li>
<li>The appointment of a fentanyl Czar to spearhead drug interdiction efforts.</li>
<li>Official designation of cartels as terrorist organizations to enable tougher enforcement measures.</li>
<li>The creation of a Canada-U.S. Joint Strike Force targeting organized crime, fentanyl networks and money laundering.</li>
<li>A $200 million intelligence directive to enhance monitoring and enforcement along the northern border.</li>
</ul>
&#8220;Proposed tariffs will be paused for at least 30 days while we work together,&#8221; the Canadian prime minister said. 
<h3 class="wp-block-heading">Markets React: Canadian Dollar Rallies, Equities Gain</h3>
The tariff deal gave a reprieve Canadian assets that were battered by heightened uncertainty earlier Monday. 
The Canadian dollar rallied, with the USD/CAD exchange rate dropping to 1.4391, down from 1.46 levels prior to the news.
Canadian equities also advanced in after-hours trading, with the iShares MSCI Canada Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWC#NYSE">EWC</a>) rising over 1%.
Read Next.
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43447339/trump-announces-us-sovereign-wealth-fund-hints-at-tiktok-ownership">Trump Orders US Sovereign Wealth Fund, Hints At TikTok Ownership: &#8216;I Have The Right To Do That&#8217;</a></li>
</ul>
Photo via Shutterstock.

Equities

Government

Regulations

Emerging Markets

Specialty ETFs

Politics

Forex

Economics

Markets

ETFs

Trump, Trudeau Strike Border Security Deal, Tariffs On Canada Paused For 'At Least 30 Days '

RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) reported quarterly earnings of $0.25 per share which missed the analyst consensus estimate of $0.36 by 30.56 percent. The company reported quarterly sales of $28.71 million which beat the analyst consensus estimate of $28.12 million by 2.10 percent. This is a 13.18 percent decrease over sales of $33.06 million the same period last year.

Earnings Misses

RBB Bancorp Q4 2024 GAAP EPS $0.25 Misses $0.36 Estimate, Sales $28.71M Beat $28.12M Estimate

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $120.17, a high estimate of $137.00, and a low estimate of $109.00. Marking an increase of 2.23%, the current average surpasses the previous average price target of $117.55. 
<img src="https://www.benzinga.com/files/images/story/2025/1738620070_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Oshkosh. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$127.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Tim Thein</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$118.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Steve Barger</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$132.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Steve Barger</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$113.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$109.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$116.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$125.00</td>
<td>$129.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Oshkosh. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Oshkosh compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Oshkosh's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Oshkosh's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OSK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Oshkosh analyst ratings.</a>
<h2>Discovering Oshkosh: A Closer Look</h2>
Oshkosh is the top producer of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, where it is typically the market share leader in North America, or, in the case of JLG aerial work platforms, a global leader. The company had manufactured joint light tactical vehicles for the us Department of Defense. However, Oshkosh recently lost the JLTV recompete, bringing into focus its us Postal Service contract, which calls for the electrification of us postal vehicles. The company reports in three segments—access equipment (52% of revenue), defense (22%), and vocational (27%)—and generated $9.6 billion in revenue in 2023.
<h3>Oshkosh: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Oshkosh faced challenges, resulting in a decline of approximately -4.3% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Oshkosh's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.84%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Oshkosh's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.71%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Oshkosh's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.58%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.23, Oshkosh adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Oshkosh Stock: Analyst Perspectives (12 Ratings)

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $273.0, with a high estimate of $286.00 and a low estimate of $265.00. This current average has increased by 3.1% from the previous average price target of $264.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1738620063_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Labcorp Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$271.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$286.00</td>
<td>$293.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$271.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$275.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Labcorp Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Labcorp Holdings's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Labcorp Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>Get to Know Labcorp Holdings Better</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Labcorp Holdings showcased positive performance, achieving a revenue growth rate of 7.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Labcorp Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Labcorp Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.09%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.96%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Labcorp Holdings's debt-to-equity ratio is below the industry average at 0.94, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Laboratory Corporation Of America Holdings

Beyond The Numbers: 6 Analysts Discuss Labcorp Holdings Stock

11 analysts have shared their evaluations of Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Illinois Tool Works, presenting an average target of $274.64, a high estimate of $318.00, and a low estimate of $250.00. Observing a 2.48% increase, the current average has risen from the previous average price target of $268.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738620048_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Illinois Tool Works. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$295.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$266.00</td>
<td>$268.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$279.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$265.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$250.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$318.00</td>
<td>$312.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$268.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$279.00</td>
<td>$266.00</td>
</tr>
<tr>
<td>Stephen Volkmann</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$290.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$270.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Underperform</td>
<td>$255.00</td>
<td>$246.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Illinois Tool Works. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Illinois Tool Works compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Illinois Tool Works's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Illinois Tool Works's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Illinois Tool Works analyst ratings.</a>
<h2>Discovering Illinois Tool Works: A Closer Look</h2>
Founded in 1912, Illinois Tool Works has become a diversified industrial manufacturer through acquisitions and innovations that follow customer needs. ITW operates through seven business segments, with no segment representing more than one fifth of revenue. ITW's automotive OEM segment sells vehicle components; its food equipment segment sells commercial kitchen appliances; its test &amp; measurement and electronics segment sells inspection and analysis equipment; its welding segment sells welding equipment and consumables; its polymers &amp; fluids segment sells industrial and consumer adhesives, solvents, and coatings; its construction products segment sells building fasteners and tools; and its specialty products segment sells medical, packaging, HVAC, and airport ground equipment.
<h3>Illinois Tool Works: Financial Performance Dissected</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Negative Revenue Trend: Examining Illinois Tool Works's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -1.61% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 29.25%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Illinois Tool Works's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 36.52%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Illinois Tool Works's ROA excels beyond industry benchmarks, reaching 7.39%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 2.46, Illinois Tool Works faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 11 Analyst Projections For Illinois Tool Works

In the preceding three months, 6 analysts have released ratings for Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $34.83, a high estimate of $38.00, and a low estimate of $32.00. Experiencing a 4.58% decline, the current average is now lower than the previous average price target of $36.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1738620040_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Weyerhaeuser by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew McKellar</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Hamir Patel</td>
<td>CIBC</td>
<td>Announces</td>
<td>Outperformer</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$33.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Buck Horne</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Ketan Mamtora</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Weyerhaeuser. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Weyerhaeuser compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Weyerhaeuser's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Weyerhaeuser's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Weyerhaeuser analyst ratings.</a>
<h2>About Weyerhaeuser</h2>
Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
<h3>A Deep Dive into Weyerhaeuser's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3 months period, Weyerhaeuser showcased positive performance, achieving a revenue growth rate of 1.61% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Weyerhaeuser's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 4.74%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Weyerhaeuser's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.82%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Weyerhaeuser's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.49%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Weyerhaeuser's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.52.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Weyerhaeuser's Future

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on aTyr Pharma (ATYR – Research Report), with a price target of ...

RBC Capital Sticks to Its Buy Rating for aTyr Pharma (ATYR)

Lucid Capital analyst Dev Prasad initiated coverage of aTyr Pharma (ATYR) with a Buy rating and $11 price target aTyr is developing a pipeline of p...

aTyr Pharma initiated with a Buy at Lucid Capital

aTyr Pharma (ATYR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on December 3. Analyst Joseph Pantginis...

aTyr Pharma's Strategic Advantage and Promising Developments in Pulmonary Sarcoidosis Treatment

aTyr Pharma (ATYR) announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia o...

aTyr Pharma to present preclinical research on ATYR0101 at symposia on Firbosis

aTyr Pharma (ATYR) announced the outcome of a third, pre-planned interim safety analysis conducted by an independent data and safety monitoring boa...

aTyr Pharma announces third positive DSMB review for efzofitimod

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on aTyr Pharma (ATYR – Research Report). The associated price target remains th...

aTyr Pharma: Promising Clinical Developments and Strategic Trial Design Drive Buy Rating

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on aTyr Pharma (ATYR – Research Report) and keeping the price target at $35.0...

Positive Outlook for aTyr Pharma: Favorable Phase 3 Progress and Competitive Advantage Highlight Buy Rating

aTyr Pharma (ATYR) announced the appointment of Eric Benevich to the Company's Board of Directors, effective as of December 10. Mr. Benevich curren...

aTyr Pharma appoints Eric Benevich to the company's Board

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma's lead drug Efzofitimod is in two trials for inte...

aTyr Pharma initiated with an Overweight at Cantor Fitzgerald

aTyr Pharma: Interesting Drug, Difficult Target Market

ATYR

Press Releases

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

Health Care

aTyr Pharma's Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting

Biotech

General

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

Comments

aTyr Pharma

aTyr Pharma (ATYR) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL